Effect of ω-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 1, 2000, Pages 259-265

  Nordøy, Arne ^a,c   Bønaa, Kaare H ^a   Sandset, Per Morten ^b   Hansen, John Bjarne ^a   Nilsen, Hugo ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Combined hyperlipemia; Hemostatic risk factors; Postprandial hyperlipemia

Indexed keywords

BLOOD CLOTTING FACTOR 8; CHOLESTEROL; OMEGA 3 FATTY ACID; SIMVASTATIN; TISSUE FACTOR PATHWAY INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033972031     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.1.259     Document Type: Article

References (45)

1. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
2. Nemerson Y. Tissue factor and haemostasis. Blood. 1988;71:1-8.
3. Østerud B, Rapaport SI, Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A. 1977;74:5260-5264.
4. Broze GJ Jr. The tissue factor pathway of coagulation: factor VII, tissue factor, and tissue factor pathway inhibitor. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EDG, eds. Haemostasis and Thrombosis. 3rd ed. New York, NY: Churchill Livingstone Inc; 1994: 349-377.
5. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 1989;86:2839-2843.
6. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988;60:453-456.
7. Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost. 1988;60:453-456.
8. Miller BC, Hultin MB, Jesty J. Altered factor VII activity in hemophilia. Blood. 1985;65:845-849.
9. Nakagaki T, Foster DC, Berkner KL, Kisiel W. Initiation of extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry. 1991;30: 10819-10824.
10. Neuenschwander PF, Morrissey JH. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function: analysis of a mutant with selective deficiency in activity. J Biol Chem. 1992;267:14477-14482.
11. Mennen LI, Schouten EG, Grobbee DE, Kluft C. Coagulation factor VII, dietary fat and blood lipids: a review. Thromb Haemost. 1996;76: 492-499.
12. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;6:533-537.
13. Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb. 1993;13:1829-1836.
14. Morrissey JH, Marci BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81: 734-744.
15. Philippou H, Adami A, Amersey RA, Stubbs PJ, Lane DA. A novel specific immunoassay for plasma two-chain factor VIIa: investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes. Blood. 1997;89:767-775.
16. Moor E, Silveira A, Hooft FV, Suontaka AM, Eriksson P, Blombäck M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age: role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol. 1995;15:655-664.
17. Goldstein JL, Schrott HG, Hazzard WR, Biereman EL, Motulsky AG. Hyperlipemia in coronary heart disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder: combined hyperlipemia. J Clin Invest. 1973;52:1544-1568.
18. deGraaf J, Stalenhoef AFH. Defects of lipoprotein metabolism in familial combined hyperlipidemia. Curr Opin Lipidol. 1998;9:189-196.
19. Hamsten A, Karpe F, Bavenholm P, Silveira A. Interactions amongst insulin, lipoproteins and haemostatic function relevant to coronary heart disease. J Intern Med. 1994;236(suppl 736):75-88.
20. Nordøy A, Bønaa KH, Nilsen H, Berge RK, Hansen JB, Ingebretsen OC. Effects of simvastatin and on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidemia. J Intern Med. 1998;243: 163-170.
21. Nordøy A, Bønaa KH, Nilsen H, Berge R, Hansen JB, Ingebrigtsen OC. Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med. 1998;243:163-170.
22. Patch JR, Karlin JR, Scott LW, Smith C, Gotto AM Jr. Inverse relationship between blood levels of high density lipoproteins and magnitude of postprandial lipemia. Proc Natl Acad Sci U S A. 1983;80:1449-1453.
23. SAS Institute. SAS/STAT User's Guide. Cary, NC: SAS Institute Inc; 1990.
24. Ruddock V, Meade TW. Factor VII activity and ischemic heart disease. Am J Med. 1994;87:403-406.
25. Hamsten A, Wiman B, deFaire B, Blombäck M. Increased plasma levels of a rapid inhibitory tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
26. Sandset PM, Abildgaard U. Extrinsic pathway inhibitor: the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis. 1991;21:219-239.
27. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Ødegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis. 1991;2:425-433.
28. Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb. 1991;11:138-145.
29. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordøy A. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb. 1994;14:223-229.
30. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hansen TA, Nordøy A. Effects of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol. 1995;15:879-885.
31. Hansen JB, Huseby NE, Sandset PM, Nordøy A. Interrelation between serum lipids and the extrinsic coagulation in middle-aged men. Haemostasis. 1998;28(suppl 2):255.
32. Silveira A, Karpe F, Blombäck M, Steiner G, Wallenius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb. 1994;14:60-90.
33. Mitropoulos KA, Miller GJ, Watts GF, Durrington PN. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor VII: a study in familial lipoprotein-lipase deficiency. Atherosclerosis. 1992;95:119-125.
34. Harris WS, Lu G, Rambjør GS, Wålen AI, Ontko JA, Cheng A, Windsor SL. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am J Clin Nutr. 1997;66:254-260.
35. Patch JR, Miesenbøck G, Hapferwieser T, Mühlberger V, Karapp E, Dunn JK, Gotto AM Jr, Patch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 1992;12:1336-1345.
36. Karpe F, Steiner G, Hoffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106:83-97.
37. Nestel JJ. Relationship between plasma triglycerides and removal of chylomicrons. J Clin Invest. 1964;43:943-949.
38. Harris WS, Connor WE, Alam N, Illingworth PR. Reduction of post-prandial triglyceridemia in humans by dietary n-3 fatty acids. J Lipid Res. 1988;29:1451-1460.
39. Hansen JB, Grimsgaard S, Nilsen H, Nordøy A, Bønaa KH. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on fatty acid absorption incorporation into serum phospholipids and postprandial triglyceridemia. Lipids. 1998;33:131-138.
40. Jeppesen J, Hollenbeck CB, Zhou MY, Coulstone AM, Jones S, Icta Chen YD, Reaven GM. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity and postprandial hyperlipemia. Arterioscler Thromb Vasc Biol. 1995;15:320-324.
41. Hendra TJ, Britton ME, Roper DR, Wagaine-Twabwe MB, Jeremy JY, Dandona P, Haines AP, Yudkin JS. Effects of fish oil supplements in NIDDM subjects. Diabetes Care. 1990;13:821-829.
42. Eritsland J, Seljeflot I, Adelnoor M, Arnesen H, Torjesen PA. Long-term effects of n-3 fatty aeids on serum lipids and glycemic control. Scand J Clin Lab Invest. 1994;54:273-280.
43. Toft I, Bønaa KH, Ingebretsen OC, Nordøy A, Jenssen T. Effects of n-3 poly-unsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. Ann Intern Med. 1995;123:911-918.
44. Andreotti F, Davies GJ, Hackett DR, Khan MI, De Bart AC, Aber VR, Maseri A, Kluft C. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden death and stroke. Am J Cardiol. 1988;62:635-637.
45. Salomaa V, Rasi V, Pekkanen J, Jauhiainen M, Vahtera E, Pietinen P, Korhonen H, Kuulasmaa K, Ehnholm C. The effects of saturated fat and n-6 postprandial hyperlipemia and hemostatic activity. Atherosclerosis. 1993;103:1-11.